LAWSUITS NEWS & LEGAL INFORMATION
ZANTAC HEARTBURN MEDICATION Legal News Articles & Interviews
January 14, 2020. By Anne Wallace.
Read [ New Research: Brief Heat Exposure Increases Zantac Cancer Odds ]
Washington, DC Emery Pharma, a California-based testing laboratory has reported that Zantac appears to produce unacceptably high levels of cancer-causing N-Nitrosodimethylamine (NDMA) when exposed to heat for as little as five days. Brief periods of modestly inadequate temperature control can easily occur during transport, storage or even in consumer’s home. These findings have sparked new calls for a U.S. Food and Drug Administration recall of Zantac and related generic drugs and will likely fuel class action Zantac cancer lawsuits (ZANTAC) already underway.
January 9, 2020. By Jane Mundy.
Read [ More Ranitidine Cancer Concerns Lead to Zantac Lawsuits ]
Santa Clara, CA Since the FDA last September reported that minute amounts of a carcinogen called N-nitrosodimethylamine (NDMA) was detected in Zantac, along with several other heartburn medications, a number of Zantac cancer lawsuits have followed.
December 9, 2019. By Jane Mundy.
Read [ Zantac – Buyer Beware, but from Whom? ]
Santa Clara, CA Since the small pharmacy Valisure waved the red flag over Zantac cancer risk, over 40 countries worldwide have stopped sales and/or began investigating the possible health risks of the heartburn drug. And Zantac lawsuits have followed. Now the FDA says it is “investigating”.
November 19, 2019. By Jane Mundy.
Read [ More Zantac Cancer Lawsuits and Recalls ]
Santa Clara, CA As more pharmaceutical companies are hit with Zantac cancer lawsuits, they are recalling the acid reflux medication in the U.S. and Canada over complaints of a link to a probable carcinogen called called N-nitrosodimethylamine (NDMA), a chemical that has already been found in animals.